08183nam 22014653u 450 991051199220332120220210180416.092-4-069266-5(CKB)3710000000198675(EBL)1741841(SSID)ssj0001401396(PQKBManifestationID)12607341(PQKBTitleCode)TC0001401396(PQKBWorkID)11349928(PQKB)10754181(MiAaPQ)EBC1741841(EXLCZ)99371000000019867520140721d2014|||| u|| |engur|n|---|||||txtccrAntimicrobial Resistance. Global Report on Surveillance[electronic resource] Global Report on SurveillanceGeneva World Health Organization20141 online resource (254 p.)Description based upon print version of record.92-4-156474-1 Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 ReferencesSECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic materialThis WHO report produced in collaboration withMember States and other partners provides as accuratea picture as is presently possible of the magnitude ofAMR and the current state of surveillance globally.The report focuses on antibacterial resistance (ABR)in common bacterial pathogens. Why? There is amajor gap in knowledge about the magnitude of thisproblem and such information is needed to guideurgent public health actions. ABR is complex andmultidimensional. It involves a range of resistancemechanisms affecting an ever-widening range ofbacteria most of which can cause a wide spectrumof diseaDrug resistance -- PeriodicalsDrug resistance in microorganismsDrug resistanceAnti-infective agentsClassificationDrug resistance in microorganismsEffect of drugs onRisk managementRiskRisk ManagementInformation ScienceDrug ResistanceMicrobiological PhenomenaEpidemiologic MeasurementsTherapeutic UsesProbabilityPharmacologic ActionsPharmacological PhenomenaPublic HealthOrganization and AdministrationStatistics as TopicHealth Services AdministrationEnvironment and Public HealthChemical Actions and UsesPhysiological PhenomenaHealth Care Evaluation MechanismsHealth CareEpidemiologic MethodsDrug TherapyQuality of Health CareInvestigative TechniquesDiagnostic Techniques and ProceduresHealth Care Quality, Access, and EvaluationAnti-Infective AgentsClassificationRisk AssessmentDrug Resistance, MicrobialBiologyHILCCHealth & Biological SciencesHILCCMicrobiology & ImmunologyHILCCElectronic books.Publication FormatsTechnical ReportDrug resistance -- Periodicals.Drug resistance in microorganisms.Drug resistance.Anti-infective agentsClassificationDrug resistance in microorganismsEffect of drugs onRisk managementRiskRisk ManagementInformation ScienceDrug ResistanceMicrobiological PhenomenaEpidemiologic MeasurementsTherapeutic UsesProbabilityPharmacologic ActionsPharmacological PhenomenaPublic HealthOrganization and AdministrationStatistics as TopicHealth Services AdministrationEnvironment and Public HealthChemical Actions and UsesPhysiological PhenomenaHealth Care Evaluation MechanismsHealth CareEpidemiologic MethodsDrug Therapy.Quality of Health CareInvestigative TechniquesDiagnostic Techniques and Procedures.Health Care Quality, Access, and EvaluationAnti-Infective AgentsClassificationRisk AssessmentDrug Resistance, MicrobialBiologyHealth & Biological SciencesMicrobiology & Immunology616Organization World Health819556World Health OrganizationWorld Health OrganizationAU-PeELAU-PeELAU-PeELBOOK9910511992203321Antimicrobial Resistance. Global Report on Surveillance2552752UNINA